AtriCure (ATRC) Stock Price, News & Analysis $34.14 +0.70 (+2.09%) (As of 12/8/2023 08:56 PM ET) Add Compare Share Share Today's Range$32.95▼$34.4650-Day Range$32.99▼$43.2552-Week Range$32.27▼$59.61Volume600,100 shsAverage Volume354,846 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$60.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media AtriCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76.1% Upside$60.13 Price TargetShort InterestBearish3.42% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$42,969 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.76) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector673rd out of 942 stocksSurgical & Medical Instruments Industry65th out of 94 stocks 3.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.13, AtriCure has a forecasted upside of 76.1% from its current price of $34.14.Amount of Analyst CoverageAtriCure has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.42% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in AtriCure has recently increased by 18.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for AtriCure this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,969.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions94.30% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.76) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -63.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -63.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AtriCure Stock (NASDAQ:ATRC)AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRC Stock News HeadlinesDecember 6, 2023 | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Given Average Recommendation of "Buy" by AnalystsDecember 2, 2023 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on Atricure (ATRC)December 11, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 1, 2023 | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Short Interest Up 18.2% in NovemberNovember 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Ambrx Biopharma (AMAM)November 29, 2023 | markets.businessinsider.comAtricure’s Strong Market Position Justifies Buy Rating Despite New CompetitionNovember 29, 2023 | markets.businessinsider.comWhere AtriCure Stands With AnalystsNovember 28, 2023 | msn.comNeedham says Medtronic could create overhang on AtriCure sharesDecember 11, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 27, 2023 | seekingalpha.comBuying These 4 Hated Names Devastated By The GLP-1 HypeNovember 15, 2023 | finance.yahoo.comWall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should KnowNovember 15, 2023 | finance.yahoo.comWall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should KnowNovember 15, 2023 | finance.yahoo.comAtriCure to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 14, 2023 | finance.yahoo.comAtriCure Releases 2023 ESG ReportNovember 10, 2023 | seekingalpha.comAtriCure: Appeal Lures For This CureNovember 6, 2023 | finance.yahoo.comAll You Need to Know About AtriCure (ATRC) Rating Upgrade to BuyNovember 4, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Atricure (ATRC)November 2, 2023 | finance.yahoo.comAtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comQ3 2023 AtriCure Inc Earnings CallNovember 1, 2023 | chron.comAtriCure: Q3 Earnings SnapshotNovember 1, 2023 | finance.yahoo.comAtriCure Reports Third Quarter 2023 Financial ResultsNovember 1, 2023 | finance.yahoo.comAtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to SayNovember 1, 2023 | finance.yahoo.comAtriCure Inc (ATRC) Reports Q3 2023 Earnings: 18.1% YoY Revenue GrowthOctober 31, 2023 | markets.businessinsider.comAtriCure earnings: here's what Wall Street expectsOctober 31, 2023 | finance.yahoo.comAtriCure to Participate in the Stifel 2023 Healthcare ConferenceOctober 25, 2023 | msn.comStocks to own ahead of a rally that this $15 billion fund house says is coming soonOctober 23, 2023 | msn.comJMP Securities Initiates Coverage of Atricure (ATRC) with Market Outperform RecommendationSee More Headlines Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,050Year Founded2000Price Target and Rating Average Stock Price Target$60.13 High Stock Price Target$74.00 Low Stock Price Target$49.00 Potential Upside/Downside+76.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,470,000.00 Net Margins-6.52% Pretax Margin-6.43% Return on Equity-6.37% Return on Assets-4.95% Debt Debt-to-Equity Ratio0.13 Current Ratio3.06 Quick Ratio2.31 Sales & Book Value Annual Sales$330.38 million Price / Sales4.90 Cash FlowN/A Price / Cash FlowN/A Book Value$9.82 per share Price / Book3.48Miscellaneous Outstanding Shares47,400,000Free Float45,973,000Market Cap$1.62 billion OptionableOptionable Beta1.35 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Michael H. Carrel (Age 52)CEO, President & Director Comp: $1.62MMs. Angela L. Wirick CPA (Age 45)Chief Financial Officer Comp: $668.62kMr. Douglas J. Seith (Age 57)Chief Operating Officer Comp: $989.17kMr. Justin J. Noznesky (Age 45)Chief Marketing & Strategy Officer Comp: $644.73kMs. Deborah Yount (Age 57)Chief Human Resources Officer Comp: $498.36kMr. Salvatore Privitera J.D. (Age 56)Chief Technical Officer Comp: $471.15kDr. Vinayak Doraiswamy Ph.D. (Age 51)Chief Scientific Officer Comp: $777.66kMr. Karl S. Dahlquist CCEP (Age 53)J.D., Chief Legal Officer Valerie Storch-WillhausVice President of Corporate Marketing & CommunicationsMore ExecutivesKey CompetitorsAlphatecNASDAQ:ATECNuVasiveNASDAQ:NUVACardiovascular SystemsNASDAQ:CSIISurmodicsNASDAQ:SRDXSilk Road MedicalNASDAQ:SILKView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 18,820 shares on 12/6/2023Ownership: 0.006%Wellington Management Group LLPSold 58,193 shares on 12/1/2023Ownership: 2.603%Decheng Capital Management III Cayman LLCBought 46,259 shares on 11/29/2023Ownership: 0.098%Deutsche Bank AGSold 6,958 shares on 11/24/2023Ownership: 0.060%Polar Capital Holdings PlcSold 10,101 shares on 11/22/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions ATRC Stock Analysis - Frequently Asked Questions Should I buy or sell AtriCure stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares. View ATRC analyst ratings or view top-rated stocks. What is AtriCure's stock price target for 2024? 7 equities research analysts have issued 12-month price targets for AtriCure's shares. Their ATRC share price targets range from $49.00 to $74.00. On average, they anticipate the company's share price to reach $60.13 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price. View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts. How have ATRC shares performed in 2023? AtriCure's stock was trading at $44.38 at the beginning of 2023. Since then, ATRC shares have decreased by 23.1% and is now trading at $34.14. View the best growth stocks for 2023 here. Are investors shorting AtriCure? AtriCure saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,620,000 shares, an increase of 18.2% from the October 31st total of 1,370,000 shares. Based on an average daily volume of 356,500 shares, the days-to-cover ratio is presently 4.5 days. View AtriCure's Short Interest. When is AtriCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our ATRC earnings forecast. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings results on Wednesday, November, 1st. The medical device company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. The medical device company earned $98.29 million during the quarter, compared to analysts' expectations of $96.65 million. AtriCure had a negative net margin of 6.52% and a negative trailing twelve-month return on equity of 6.37%. The company's quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.27) EPS. What ETFs hold AtriCure's stock? ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), Simplify Health Care ETF (PINK), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI). What is Michael Carrel's approval rating as AtriCure's CEO? 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT). Who are AtriCure's major shareholders? AtriCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (3.03%), Wellington Management Group LLP (2.60%), Invesco Ltd. (2.18%), TimesSquare Capital Management LLC (1.91%), Loomis Sayles & Co. L P (1.82%) and Fiera Capital Corp (1.45%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does AtriCure have any subsidiaries? The following companies are subsidiares of AtriCure: SentreHEART.Read More This page (NASDAQ:ATRC) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.